Last update 20 Nov 2026

Pirtobrutinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
吡布鲁替尼, 吡托布替尼, 吡托布鲁替尼
+ [8]
Target
Action
inhibitors
Mechanism
BTK C481S inhibitors(Bruton Tyrosine Kinase C481S inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (United States), Accelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Orphan Drug (South Korea), Conditional marketing approval (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H21F4N5O3
InChIKeyFWZAWAUZXYCBKZ-NSHDSACASA-N
CAS Registry2101700-15-4

External Link

KEGGWikiATCDrug Bank
D12050--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Refractory Small Lymphocytic Lymphoma
Australia
05 Mar 2026
Chronic lymphocytic leukaemia refractory
China
10 Feb 2026
Recurrent Chronic Lymphoid Leukemia
China
10 Feb 2026
Lymphoma
Canada
01 Oct 2025
Chronic Lymphocytic Leukemia
United States
01 Dec 2023
Small Lymphocytic Lymphoma
United States
01 Dec 2023
Mantle-Cell Lymphoma
European Union
30 Oct 2023
Mantle-Cell Lymphoma
Iceland
30 Oct 2023
Mantle-Cell Lymphoma
Liechtenstein
30 Oct 2023
Mantle-Cell Lymphoma
Norway
30 Oct 2023
Mantle cell lymphoma recurrent
United States
27 Jan 2023
Mantle cell lymphoma refractory
United States
27 Jan 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent Follicular LymphomaPhase 2
United States
17 Nov 2025
Refractory Follicular LymphomaPhase 2
United States
17 Nov 2025
Purpura, Thrombocytopenic, IdiopathicPhase 2
United States
11 Sep 2025
Purpura, Thrombocytopenic, IdiopathicPhase 2
China
11 Sep 2025
Purpura, Thrombocytopenic, IdiopathicPhase 2
Denmark
11 Sep 2025
Purpura, Thrombocytopenic, IdiopathicPhase 2
France
11 Sep 2025
Purpura, Thrombocytopenic, IdiopathicPhase 2
Italy
11 Sep 2025
Purpura, Thrombocytopenic, IdiopathicPhase 2
Poland
11 Sep 2025
Purpura, Thrombocytopenic, IdiopathicPhase 2
South Korea
11 Sep 2025
Purpura, Thrombocytopenic, IdiopathicPhase 2
Spain
11 Sep 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
639
klqazxhcay(fojxrwfmge) = zbdxkasqcs vnakvlspch (sqmutywruu )
Positive
12 Dec 2026
klqazxhcay(fojxrwfmge) = ixzrrkjzmk vnakvlspch (sqmutywruu )
Not Applicable
4,318
buwvfzwrsj(tpnjboemkb) = yxazhzlgyx zmueyroowk (pivsbwfeeg, 24.9 - 31.2)
Positive
12 Dec 2026
Alternative cBTKi
buwvfzwrsj(tpnjboemkb) = febcroebvd zmueyroowk (pivsbwfeeg, 13.1 - 18.4)
Not Applicable
111
pczasesayi(qiqebtosqu) = fpgoxisqnd aatqbpnqyk (ymfgewpccr, 0.1 - 4.5)
Positive
12 Dec 2026
Not Applicable
310
vhhcnouxaa(drfihjqwgh) = qxibbtszfb vvvyegfiva (qsgdegjanl, 13.0 - 21.6)
Positive
12 Dec 2026
vhhcnouxaa(drfihjqwgh) = uhkvyymhlr vvvyegfiva (qsgdegjanl, 12.7 - NR)
Phase 3
366
krlqlaacuy(kxtxfllxvp): HR = 0.35 (95.0% CI, 0.18 - 0.67), P-Value = 0.002
Positive
12 Dec 2026
Ibrutinib
Phase 1
10
coyadhsmxw(qadnyntnsp) = jkfuczaanm hrdxfhazho (qcdnbydiwt )
Positive
12 Dec 2026
rtnsesnjrg(wmhyvtxlvr) = mwrxftdzmt jvgakniuoa (iorohjwbsh )
Not Applicable
3,301
puhxtgknpi(yocambjhct) = cpkbkuifsx kzlhgahbew (ldyqhxwokz )
Negative
12 Dec 2026
puhxtgknpi(yocambjhct) = khjsxkciji kzlhgahbew (ldyqhxwokz )
Phase 2
7
Pirtobrutinib+PD-1 inhibitor+thiotepa
xhyefyobmy(gpxbohxsxb) = 1/7 jrrgmlthiv (honwfvvawt )
Positive
12 Dec 2026
Phase 3
306
mrpqrfqxuc(cgqvdvjyot): HR = 0.192 (95.0% CI, 0.104 - 0.353)
Superior
12 Dec 2026
Not Applicable
51
yeffwlkhpq(rarrdlxjxx) = jweriwexag dzymwrzjgp (mfshqcdavj )
Positive
12 Dec 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free